Social Media Ideas for Glncy

Glencore said to have set aside $480M provision for Radiant World exposure

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Liberty Capital Corp. (GLIBK): Reassessing Catalysts, Sentiment, and Governance

GSK plc (GSK) Q2 2026 Earnings Call Transcript

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

GSK: Still One Of My Top Healthcare Picks

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

GeneChem Inc. Receives U.S. FDA NDIN No Objection for Siallac6®, 6'-Sialyllactose Sodium Salt in Collaboration with REJI...

GeneChem Inc., a biotechnology company specializing in AI-powered enzyme engineering and the development of high-value biomaterials, today announced that the U.S. Food and Drug Adm...

Blenrep

Blenrep Anonymous (not verified) Tue, 09/08/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...

Riverwater Sees a Market Overreaction in Stevanato Group (STVN) After Oral GLP-1 Launches

Ultragenyx, after setbacks, nabs first gene therapy approval

The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.

NTG Clarity Networks Inc. (NCI:CA) Q2 2026 Earnings Call Transcript

Global Partners LP Common Units 2026 Q2 - Results - Earnings Call Presentation

Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Dru...

GNS Deadline: GNS Investors with Losses in Excess of $100K Have Opportunity to Lead Genius Group Limited Securities Frau...

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of securities of Genius Group Limited (NYSE American: GNS)...

Many bought this stock to play the GLP-1 boom, but it has bigger opportunities to boost its share price

Instead of betting on which single pharmaceutical company wins a drug race, this company benefits as the industry grows by supplying the proprietary packaging.

Lyntris files for IPO, plans to list on NYSE under "LYNX"

StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss

Lilly now expects to rack up between $85 billion and $87 billion in revenue this year, up 2.4% to 3.7% from its previous range of between $82 billion and $85 billion. That change r...

LGL Group: A Speculative Bet On Operational Improvement And Capital Deployment

YieldMax Gold Miners Option Income Strategy ETF announces weekly distribution of $0.0942

Gentex declares $0.12 dividend